CymaBay Therapeutics

134 articles about CymaBay Therapeutics

• CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

  6/7/2023

  CymaBay Therapeutics, Inc. announced it will make three presentations at the European Association for the Study of the Liver 's The International Liver Congress™ 2023.

• CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/15/2023

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases, today announced corporate updates and financial results for the first quarter ended March 31, 2023.

• CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023

  5/10/2023

  CymaBay Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update.

• CymaBay Names Harish Shantharam Chief Financial Officer

  5/9/2023

  CymaBay Therapeutics, Inc. announced that seasoned biopharma executive Harish Shantharam, CFA has joined the company as Chief Financial Officer.

• CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

  4/21/2023

  CymaBay Therapeutics, Inc. today announced that results from the ENHANCE phase 3 global study evaluating seladelpar for primary biliary cholangitis (PBC) have been published in Hepatology.

• CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

  4/17/2023

  CymaBay Therapeutics, Inc. today announced that management will participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ.

• CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update

  3/16/2023

  CymaBay Therapeutics, Inc. announced corporate updates and financial results for the year and fourth quarter ended December 31, 2022.

• CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

  3/9/2023

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that it will host a conference call and live audio webcast on Thursday, March 16, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2022 and to provide a business update.

• CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

  3/1/2023

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd Annual Healthcare Conference.

• CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference

  2/6/2023

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference.

• CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  1/30/2023

  CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously announced underwritten public offering of its common stock and pre-funded warrants. 

• CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - January 24, 2023

  1/24/2023

  CymaBay Therapeutics, Inc. today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants.

• CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Jan 23, 2023

  1/23/2023

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

• CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

  1/8/2023

  CymaBay Therapeutics, Inc. announced that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization in Japan of CymaBay’s investigational drug seladelpar for the treatment of primary biliary cholangitis.

• CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate UpdateConference call and webcast today at 4:30 p.m. ET

  11/14/2022

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced corporate updates and financial results for the third quarter ended September 30, 2022.

• CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022

  11/7/2022

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2022 and to provide a business update.

• 

  Movers & Shakers: Ambrx, ADC Therapeutics, ImmunoGen and More get New C-Suites

  11/4/2022

  The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.

• CymaBay Therapeutics to Present at Upcoming Investment Conferences - November 03, 2022

  11/3/2022

  CymaBay Therapeutics, Inc. announced that management will participate in the Credit Suisse 31st Healthcare Conference taking place November 7-10, 2022 in Rancho Palos Verdes, CA and the 34th Annual Piper Sandler Healthcare Conference taking place November 29 to December 1, 2022 in New York, NY.

• CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development

  11/1/2022

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the appointment of Dr. Charles McWherter as President of Research and Development.

• CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022

  10/3/2022

  CymaBay Therapeutics, Inc. today announced that three abstracts related to its seladelpar development program for the treatment of primary biliary cholangitis (PBC) will be presented at The Liver Meeting ® of the American Association for the Study of Liver Diseases (AASLD).